SerpApi.Org
WASHINGTON - Losing weight used to mean picking a lane: diet and exercise, prescription, or surgery. Pick the wrong one, or stick with it too long past the point it stopped working, and progress stalls. For a condition affecting a significant share of American adults, that narrow menu never matched how complicated obesity actually is.
Drugs like Ozempic and Zepbound have changed that conversation dramatically over the past several years. But according to doctors who treat obesity for a living, the medications are one piece of a much bigger puzzle. New research digs into what the rest of that puzzle looks like - and who should be helping patients put it together.
Revisiting POWER in the GLP-1 Age
Obesity care has gone through a genuine transformation over the past decade, and doctors are now rethinking what comprehensive treatment should look like. Researchers at the American Gastroenterological Association had their new commentary published in the Gastroenterology Journal in June 2026.
The goal was to update that framework for a landscape barely resembling the one for which it was built.
What's Changed Since 2017The original framework, known as POWER (Practice Guide on Obesity and Weight Management, Education, and Resources), provided doctors with a structured approach to guide patients through obesity treatment. It’s been widely adopted across gastroenterology and hepatology practices since its release.
A lot has shifted since then. GLP-1 receptor agonists - the class of drugs that includes semaglutide like Ozempic and Wegovy, and tirzepatide like Zepbound and Mounjaro - have become mainstream treatment options.
At the same time, less invasive procedures have improved. One example is endoscopic sleeve gastroplasty, a procedure that reshapes the stomach using an endoscopic suturing device rather than traditional surgery. A major clinical trial found that patients who underwent the procedure lost significantly more weight than those who didn’t, with the majority keeping some or most of the weight off two years later.
Bariatric surgery has also expanded to cover more patients, and researchers have made progress in understanding the genetics behind why certain people respond better to certain treatments than others.
Obesity as a Chronic, Whole-Body ConditionPart of the update involves how doctors define obesity in the first place. Body mass index, or BMI, has long been the default measurement, but the researchers point out that BMI alone doesn’t capture the full picture of a person’s health risk. A related concept, “clinical obesity,” has emerged to describe cases in which excess body fat begins to affect the function of organs or tissues throughout the body, rather than just body weight on a scale.
The researchers also connect obesity to a broader web of conditions, including diabetes, kidney and liver disorders, and cardiovascular disease, describing this cluster as a shared, interconnected health risk rather than separate issues to treat in isolation.
One Tool Isn't EnoughPerhaps the clearest theme in the update is that no single treatment works best on its own for most patients. Lifestyle changes like nutrition and physical activity remain foundational, but the researchers note they’re often not enough on their own to produce lasting weight loss, given the biological factors working against patients.
Instead, the commentary points to combining approaches for better results. In one study cited by the authors, patients who paired an endoscopic procedure with a GLP-1 medication lost significantly more weight than those who had the procedure alone. The researchers frame this as evidence that medications, endoscopic therapies, and surgery work better as complementary tools tailored to the individual patient, rather than as competing options.
Who's Involved In This CareThe commentary makes a specific case for the role gastroenterologists and hepatologists play in treating obesity. These specialists already see many of the conditions that overlap heavily with obesity, including acid reflux, gallbladder disease, and metabolic dysfunction-associated steatotic liver disease, a condition where fat builds up in the liver.
Because these doctors are already managing the downstream effects of excess weight, the researchers argue they’re well-positioned to guide treatment as the field evolves, both by prescribing medications and performing endoscopic procedures themselves.
Future Implications
The authors describe this update as a living document rather than a finished guideline, meant to be revised again as new treatments and evidence emerge. They point to genetics and precision medicine as an area with particular promise, with early research suggesting that patients with different biological profiles may respond to different treatments. The idea is to eventually help doctors match patients to the approach most likely to work for them from the start, rather than relying on trial-and-error.
A Bigger Toolbox for a Complicated Condition
The bigger picture here is less about any single drug or procedure and more about how doctors are learning to think about obesity treatment as a whole. As more tools become available, the researchers suggest, the path forward is to build a plan that can flex and combine approaches as a patient’s needs change over time.
Our website content, services and products are for informational purposes only. The Well News does not provide medical advice, diagnosis or treatment. If you have medical concerns or questions, discuss with your health care professional.
You can reach us at [email protected] and follow us on Facebook and X
The post GLP-1 Drugs Changed Obesity Care, Doctors Say They're Just the Start appeared first on The Well News | Pragmatic, Governance, Fiscally Responsible, News & Analysis.
